Biotech M&A – 2021 Deals

Biotech M&A – 2021 Deals

Biotech M&A With a Slow Start in 2020: More Deals to Follow?

DateAcquirer Co.Acquirer TickerAcquired Co.Acquired TickerDeal valuePrice/ShareNotesLink to the news PR
01/05/2021Hologic, Inc.HOLXSOMATEX Private-German co.$64M-leader in biopsy site markers
01/07/2021 PerkinElmerPKI Oxford Immunotec OXFD $591M $22 infectious disease testing
01/08/2021ChimerixCMRXOncoceutics, Inc.Private co.$78M-Recurrent H3 K27M-mutant Glioma
02/01/2021Horizon TherapeuticsHZNPViela BioVIE$3.05B$53commercial rare disease medicine portfolio with UPLIZNA
02/03/2021Jazz Pharmaceuticals JAZZGW PharmaceuticalsGWPH$7.2B$$220Cannabidiol - Epidiolex
$200 in cash & $20 in Jazz shares
02/23/2021Beam TherapeuticsBEAMGuide TherapeuticsPrivate co.$120M in BEAM stockslipid nanoparticle (LNP)
02/25/2021MerckMRKPandion TherapeuticsPAND$1.85B$60IL-2 & Autoimmune
03/03/2021AmgenAMGNFive Prime TherapeuticsFPRX$1.9B$38Bemarituzumab, Ph3 for Gastric Cancer

For M&A 2020 full table click here

Recent Press


Log In

JoinLost Password?